Status:
COMPLETED
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborating Sponsors:
Biogen
Conditions:
Non-Hodgkins Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this trial, we will evaluate the feasibility, toxicity, and effectiveness ibritumomab tiuxetan, when incorporated into combination first-line treatment for follicular lymphoma. Addition of the ibri...
Detailed Description
Upon determination of eligibility, patients will be receive: * Rituxan + CHOP or CVP + Ibritumomab Tiuxetan Patients who are considered medical candidates for doxorubicin should receive CHOP chemoth...
Eligibility Criteria
Inclusion
- To be included in this study, you must meet the following criteria:
- Histologic documentation of follicular center, B-cell lymphoma
- Early stage lymphoma (stages I or II) relapsed after radiation therapy alone
- No previous chemotherapy or monoclonal antibody therapy
- Measurable or evaluable disease
- Able to perform activities of daily living with minimal assistance
- Age \> 18 years
- Adequate bone marrow ,liver and kidney function
- Must be accessible for treatment and follow-up.
- Bone marrow examination initial staging and accurate restaging
- All patients must give written informed consent prior to study entry.
Exclusion
- You cannot participate in this study if any of the following apply to you:
- Small lymphocytic (CLL type) lymphomas and CLL
- Impaired bone marrow reserve
- Female pregnant or lactating
- Serious active infection at the time of treatment
- Any other serious underlying condition
- Central nervous system involvement (brain or meningeal)
- HIV or AIDS-related lymphoma
- Received prior external beam radiation therapy to \> 25% of active bone marrow
- Pleural effusion
- Received prior murine antibodies or proteins
- History of other neoplasms within five years of diagnosis
- Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Key Trial Info
Start Date :
April 1 2002
Trial Type :
INTERVENTIONAL
End Date :
January 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00193440
Start Date
April 1 2002
End Date
January 1 2009
Last Update
December 30 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.